New tax FAQs highlight Egypt's strategy to widen tax base, boost trust    IL Cazar Launches 'WestDays' Project in October City with EGP 20 Billion Investment    US, China to hold high-level trade talks in Switzerland    India strikes Pakistan, Islamabad claims 5 Indian jets downed amid escalation    Saudi Arabia Hosts First Asian Physics Olympiad in the Middle East    Egypt voices deep concern over India-Pakistan escalation    Egypt welcomes Oman-brokered US-Yemen ceasefire agreement    Egypt inks deal with Merck to advance healthcare training    Egypt's GAHAR, Expertise France to elevate healthcare quality    EGP inches up against USD in early trade    Egypt's El Khatib, EBRD Head discuss deeper EU investment    Pakistan PM says nation giving "Befitting Reply" to Indian strikes    Health Minister orders expansion of residency training programmes to strengthen medical workforce    Egypt's FRA warns against unlicensed financial investment schemes    Gaza faces humanitarian collapse amid escalating Israeli offensive, healthcare breakdown    CIB Egypt extends EGP 2.45bn bridge loan to SODIC for North Coast 'June' project    Al Ismaelia, Coventry University Cairo partner on urban development education    Egypt's EDA backs local vaccine industry    Egyptian FM addresses Arab Women Organization Conference opening    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Cabinet approves establishment of national medical tourism council to boost healthcare sector    "5,000 Years of Civilizational Dialogue" theme for Korea-Egypt 30th anniversary event    Sudan conflict, bilateral ties dominate talks between Al-Sisi, Al-Burhan in Cairo    Cairo's Madinaty and Katameya Dunes Golf Courses set to host 2025 Pan Arab Golf Championship from May 7-10    Between Women Filmmakers' Caravan opens 5th round of Film Consultancy Programme for Arab filmmakers    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Ancient military commander's tomb unearthed in Ismailia    Egypt's FM inspects Julius Nyerere Dam project in Tanzania    Egypt's FM praises ties with Tanzania    Egypt to host global celebration for Grand Egyptian Museum opening on July 3    Ancient Egyptian royal tomb unearthed in Sohag    Egyptian Minister praises Nile Basin consultations, voices GERD concerns    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



CVC, Temasek buys $2bln Generic Drugs Frim Alvogen- Reuters
Published in Amwal Al Ghad on 22 - 06 - 2015

European private equity fund CVC and Singaporean sovereign wealth fund Temasek [TEM.UL] are to buy a controlling stake in the pharmaceutical firm Alvogen, its chairman and chief executive said.
Robert Wessman, former CEO of Actavis, founded the New Jersey-based generic drugs firm in 2009.
The size of the stake the consortium purchased was not disclosed, but the deal values the company at around $2 billion, a source familiar with the matter said on Monday.
The transaction is the latest sign of the hectic pace of deal-making in the healthcare sector, which has seen more than $250 billion of mergers and acquisitions so far this year, up nearly two-thirds from a year ago, according to Thomson Reuters data.
Wessman sold a stake in Alvogen to the private equity fund Pamplona in 2014. The new owners also include U.S. investment group Vatera Healthcare Partners. Wessman and Pamplona will retain a stake.
The fast-growing company currently has 350 generic products on the market and has been pushing into the Asia-Pacific region with several acquisitions, including that of South Korea's Dream Pharma last year.
"We have grown from a small base in the U.S. back in 2009 to a global player with operations in 35 countries," Wessman told Reuters. "Our growth has been 76 percent a year in the past six years, a majority being organic, but with access to network and capital from our partners you should expect to see more acquisitions."
Generic drugmakers like Alvogen are looking to get bigger to enjoy economies of scale in manufacturing and distribution, while CVC has an interest in health through previous deals, such as a 2012 investment in Chinese drugmaker Venturepharma.
"We want to be a company that can build up one of the leading positions in Asia Pacific, and on a global level we expect to be among the leading companies in a few years from now," Wessman said.
He explained Alvogen's strategy as focusing on high-growth emerging markets, developing a "difficult to make" product portfolio in the U.S. market, and building a strong presence in copies of biotech drugs or biosimilars.
Generic drugs are manufactured once the patent for a branded drug has expired and sold far more cheaply than their original counterparts.
Wessman and his team face increasingly tough competition, as rivals also bulk up through takeovers or mergers, with Israel's Teva Pharmaceutical Industries (TEVA.TA) currently in a $40 billion pursuit of Mylan (MYL.O).
Alvogen's current revenue this year stands at $750 million, with core earnings (EBITDA) of $220 million.
CVC has just bought the theater production company Stage and the German perfume business Douglas, and recently hired Goldman Sachs (GS.N) dealmaker Alex Dibelius as a managing partner.
Jefferies acted as financial adviser to the investment consortium, while Goldman Sachs advised Alvogen and Pamplona.
Source: Reuters


Clic here to read the story from its source.